Dr. Dan Landau

A set of powerful laboratory and computational techniques developed by scientists at Weill Cornell Medicine, the New York Genome Center (NYGC) and the Broad Institute will enable investigators to map the capacity of tumors to develop resistance to drugs and drug combinations. 

A new technology devised by scientists at Weill Cornell Medicine and the New York Genome Center (NYGC) enables the measurement of gene mutations and their effects on gene activity within individual cancer cells biopsied from patients.

A powerful new set of scientific tools developed by Weill Cornell Medicine and New York Genome Center (NYGC) researchers enables them to track the molecular evolution of cancers. 

The second annual Dean’s Symposium on Opportunities for Entrepreneurship and Academic Drug Development highlighted the resources available to Weill Cornell Medicine investigators to help them turn their research findings into new treatments and therapies for patients.

Dr. Dan Landau has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

A type of stem cell newly discovered by Weill Cornell Medicine and NewYork-Presbyterian investigators is responsible for growing and healing the hard, outer surface of bone.

Dr. Dan Landau, an assistant professor of medicine and of physiology and biophysics at Weill Cornell Medicine, and a core faculty member of the New York Genome Center, has been awarded the Pershing Square Sohn Prize for Young Investigators in Cancer Research to support his work studying cancer evolution.

Ongoing monitoring for genetic changes in chronic lymphocytic leukemia (CLL) during targeted treatment may allow clinicians to adjust patients’ treatments as the cancer evolves, according to a study in Nature Communications led by Weill Cornell Medicine and New York Genome Center scientists.

Awards, honors, prizes and achievements for the month of June.